APO Research
Talk to an analyst

APO RESEARCH · REPORT

Afatinib

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Afatinib Market Analysis and Forecast 2026-2032

23 December 2025193 pages

Choose your research edition.

Industry ResearchAfatinib Industry Research Report 2026101 pages · $2,950 USDIndustry Growth & TrendsGlobal Afatinib Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal Afatinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Afatinib Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Afatinib Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Afatinib market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Afatinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Afatinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Afatinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Afatinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Afatinib include Boehringer Ingelheim, Beacon Pharma and Hengrui Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Afatinib, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Afatinib, also provides the revenue of main regions and countries. Of the upcoming market potential for Afatinib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Afatinib revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Afatinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Afatinib revenue, projected growth trends, production technology, application and end-user industry.

Afatinib Segment by Company

Boehringer Ingelheim

Beacon Pharma

Hengrui Medicine

Afatinib Segment by Type

50mg Tables

40mg Tables

30mg Tables

25mg Tables

20mg Tables

Others

Afatinib Segment by Application

Drug Center

Hospital

Clinic

Others

Afatinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Afatinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Afatinib in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Afatinib company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Afatinib revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Afatinib Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 50mg Tables Major Player Table 3. 40mg Tables Major Player Table 4. 30mg Tables Major Player Table 5. 25mg Tables Major Player Table 6. 20mg Tables Major Player Table 7. Others Major Player Table 8. Global Afatinib Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Drug Center Major Player Table 10. Hospital Major Player Table 11. Clinic Major Player Table 12. Others Major Player Table 13. Afatinib Industry Trends Table 14. Afatinib Industry Drivers Table 15. Afatinib Industry Opportunities and Challenges Table 16. Afatinib Industry Restraints Table 17. Global Afatinib Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Afatinib Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Afatinib Market Share by Region (2021-2026) Table 20. Global Afatinib Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Afatinib Market Share by Region (2027-2032) Table 22. Global Afatinib Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Afatinib Revenue Market Share by Players (2021-2026) Table 24. Global Afatinib Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Afatinib Key Players Headquarters & Area Served Table 26. Global Afatinib Players, Product Type & Application Table 27. Global Afatinib Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Afatinib by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Afatinib Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Afatinib Revenue Market Share by Type (2021-2026) Table 34. Global Afatinib Revenue Market Share by Type (2027-2032) Table 35. Global Afatinib Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Afatinib Revenue Market Share by Application (2021-2026) Table 39. Global Afatinib Revenue Market Share by Application (2027-2032) Table 40. Boehringer Ingelheim Company Information Table 41. Boehringer Ingelheim Business Overview Table 42. Boehringer Ingelheim Afatinib Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Boehringer Ingelheim Afatinib Product Portfolio Table 44. Boehringer Ingelheim Recent Development Table 45. Beacon Pharma Company Information Table 46. Beacon Pharma Business Overview Table 47. Beacon Pharma Afatinib Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Beacon Pharma Afatinib Product Portfolio Table 49. Beacon Pharma Recent Development Table 50. Hengrui Medicine Company Information Table 51. Hengrui Medicine Business Overview Table 52. Hengrui Medicine Afatinib Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Hengrui Medicine Afatinib Product Portfolio Table 54. Hengrui Medicine Recent Development Table 55. North America Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 56. North America Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 57. North America Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 58. North America Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 59. North America Afatinib Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America Afatinib Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Afatinib Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe Afatinib Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe Afatinib Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe Afatinib Revenue by Country (US$ Million) & (2027-2032) Table 69. China Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 70. China Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 71. China Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 72. China Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia Afatinib Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia Afatinib Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia Afatinib Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA Afatinib Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA Afatinib Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA Afatinib Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA Afatinib Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA Afatinib Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA Afatinib Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA Afatinib Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Afatinib Image Figure 2. Global Afatinib Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Afatinib Market Size Share 2021 VS 2025 VS 2032 Figure 4. 50mg Tables Image Figure 5. 40mg Tables Image Figure 6. 30mg Tables Image Figure 7. 25mg Tables Image Figure 8. 20mg Tables Image Figure 9. Others Image Figure 10. Global Afatinib Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Afatinib Market Size Share 2021 VS 2025 VS 2032 Figure 12. Drug Center Image Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Others Image Figure 16. Global Afatinib Market Size (US$ Million) & (2021-2032) Figure 17. Global Afatinib Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Afatinib Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Afatinib Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Afatinib Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Afatinib Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Afatinib Revenue Market Share by Type (2021-2032) Figure 24. Global Afatinib Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Afatinib Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Afatinib Revenue Market Share by Application (2021-2032) Figure 27. North America Afatinib Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Afatinib Revenue Share by Type (2021-2032) Figure 29. North America Afatinib Revenue Share by Application (2021-2032) Figure 30. North America Afatinib Revenue Share by Country (2021-2032) Figure 31. United States Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Afatinib Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Afatinib Revenue Share by Type (2021-2032) Figure 36. Europe Afatinib Revenue Share by Application (2021-2032) Figure 37. Europe Afatinib Revenue Share by Country (2021-2032) Figure 38. Germany Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Afatinib Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Afatinib Revenue Share by Type (2021-2032) Figure 48. China Afatinib Revenue Share by Application (2021-2032) Figure 49. Asia Afatinib Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Afatinib Revenue Share by Type (2021-2032) Figure 51. Asia Afatinib Revenue Share by Application (2021-2032) Figure 52. Asia Afatinib Revenue Share by Region (2021-2032) Figure 53. Japan Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Afatinib Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Afatinib Revenue Share by Type (2021-2032) Figure 61. SAMEA Afatinib Revenue Share by Application (2021-2032) Figure 62. SAMEA Afatinib Revenue Share by Country (2021-2032) Figure 63. Brazil Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Afatinib Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg Tables
  • 40mg Tables
  • 30mg Tables
  • 25mg Tables
  • 20mg Tables
  • Others
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Boehringer Ingelheim
  • Beacon Pharma
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Afatinib Market by Type
  3. 1.2.1 Global Afatinib Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 50mg Tables
  5. 1.2.3 40mg Tables
  6. 1.2.4 30mg Tables
  7. 1.2.5 25mg Tables
  8. 1.2.6 20mg Tables
  9. 1.2.7 Others
  10. 1.3 Afatinib Market by Application
  11. 1.3.1 Global Afatinib Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Drug Center
  13. 1.3.3 Hospital
  14. 1.3.4 Clinic
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Afatinib Market Dynamics
  1. 2.1 Afatinib Industry Trends
  2. 2.2 Afatinib Industry Drivers
  3. 2.3 Afatinib Industry Opportunities and Challenges
  4. 2.4 Afatinib Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Afatinib Market Perspective (2021-2032)
  2. 3.2 Global Afatinib Growth Trends by Region
  3. 3.2.1 Global Afatinib Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Afatinib Market Size by Region (2021-2026)
  5. 3.2.3 Global Afatinib Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Afatinib Revenue by Players
  2. 4.1.1 Global Afatinib Revenue by Players (2021-2026)
  3. 4.1.2 Global Afatinib Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Afatinib Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Afatinib Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Afatinib Key Players Headquarters & Area Served
  7. 4.4 Global Afatinib Players, Product Type & Application
  8. 4.5 Global Afatinib Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Afatinib Market CR5 and HHI
  11. 4.6.3 2025 Afatinib Tier 1, Tier 2, and Tier 3
5 Afatinib Market Size by Type
  1. 5.1 Global Afatinib Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Afatinib Revenue by Type (2021-2032)
  3. 5.3 Global Afatinib Revenue Market Share by Type (2021-2032)
6 Afatinib Market Size by Application
  1. 6.1 Global Afatinib Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Afatinib Revenue by Application (2021-2032)
  3. 6.3 Global Afatinib Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Boehringer Ingelheim
  2. 7.1.1 Boehringer Ingelheim Company Information
  3. 7.1.2 Boehringer Ingelheim Business Overview
  4. 7.1.3 Boehringer Ingelheim Afatinib Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Boehringer Ingelheim Afatinib Product Portfolio
  6. 7.1.5 Boehringer Ingelheim Recent Developments
  7. 7.2 Beacon Pharma
  8. 7.2.1 Beacon Pharma Company Information
  9. 7.2.2 Beacon Pharma Business Overview
  10. 7.2.3 Beacon Pharma Afatinib Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Beacon Pharma Afatinib Product Portfolio
  12. 7.2.5 Beacon Pharma Recent Developments
  13. 7.3 Hengrui Medicine
  14. 7.3.1 Hengrui Medicine Company Information
  15. 7.3.2 Hengrui Medicine Business Overview
  16. 7.3.3 Hengrui Medicine Afatinib Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Hengrui Medicine Afatinib Product Portfolio
  18. 7.3.5 Hengrui Medicine Recent Developments
8 North America
  1. 8.1 North America Afatinib Revenue (2021-2032)
  2. 8.2 North America Afatinib Revenue by Type (2021-2032)
  3. 8.2.1 North America Afatinib Revenue by Type (2021-2026)
  4. 8.2.2 North America Afatinib Revenue by Type (2027-2032)
  5. 8.3 North America Afatinib Revenue Share by Type (2021-2032)
  6. 8.4 North America Afatinib Revenue by Application (2021-2032)
  7. 8.4.1 North America Afatinib Revenue by Application (2021-2026)
  8. 8.4.2 North America Afatinib Revenue by Application (2027-2032)
  9. 8.5 North America Afatinib Revenue Share by Application (2021-2032)
  10. 8.6 North America Afatinib Revenue by Country
  11. 8.6.1 North America Afatinib Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Afatinib Revenue by Country (2021-2026)
  13. 8.6.3 North America Afatinib Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Afatinib Revenue (2021-2032)
  2. 9.2 Europe Afatinib Revenue by Type (2021-2032)
  3. 9.2.1 Europe Afatinib Revenue by Type (2021-2026)
  4. 9.2.2 Europe Afatinib Revenue by Type (2027-2032)
  5. 9.3 Europe Afatinib Revenue Share by Type (2021-2032)
  6. 9.4 Europe Afatinib Revenue by Application (2021-2032)
  7. 9.4.1 Europe Afatinib Revenue by Application (2021-2026)
  8. 9.4.2 Europe Afatinib Revenue by Application (2027-2032)
  9. 9.5 Europe Afatinib Revenue Share by Application (2021-2032)
  10. 9.6 Europe Afatinib Revenue by Country
  11. 9.6.1 Europe Afatinib Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Afatinib Revenue by Country (2021-2026)
  13. 9.6.3 Europe Afatinib Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Afatinib Revenue (2021-2032)
  2. 10.2 China Afatinib Revenue by Type (2021-2032)
  3. 10.2.1 China Afatinib Revenue by Type (2021-2026)
  4. 10.2.2 China Afatinib Revenue by Type (2027-2032)
  5. 10.3 China Afatinib Revenue Share by Type (2021-2032)
  6. 10.4 China Afatinib Revenue by Application (2021-2032)
  7. 10.4.1 China Afatinib Revenue by Application (2021-2026)
  8. 10.4.2 China Afatinib Revenue by Application (2027-2032)
  9. 10.5 China Afatinib Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Afatinib Revenue (2021-2032)
  2. 11.2 Asia Afatinib Revenue by Type (2021-2032)
  3. 11.2.1 Asia Afatinib Revenue by Type (2021-2026)
  4. 11.2.2 Asia Afatinib Revenue by Type (2027-2032)
  5. 11.3 Asia Afatinib Revenue Share by Type (2021-2032)
  6. 11.4 Asia Afatinib Revenue by Application (2021-2032)
  7. 11.4.1 Asia Afatinib Revenue by Application (2021-2026)
  8. 11.4.2 Asia Afatinib Revenue by Application (2027-2032)
  9. 11.5 Asia Afatinib Revenue Share by Application (2021-2032)
  10. 11.6 Asia Afatinib Revenue by Country
  11. 11.6.1 Asia Afatinib Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Afatinib Revenue by Country (2021-2026)
  13. 11.6.3 Asia Afatinib Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Afatinib Revenue (2021-2032)
  2. 12.2 SAMEA Afatinib Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Afatinib Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Afatinib Revenue by Type (2027-2032)
  5. 12.3 SAMEA Afatinib Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Afatinib Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Afatinib Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Afatinib Revenue by Application (2027-2032)
  9. 12.5 SAMEA Afatinib Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Afatinib Revenue by Country
  11. 12.6.1 SAMEA Afatinib Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Afatinib Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Afatinib Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst